TY - JOUR
T1 - Racial differences in real-world outcomes of first-line therapies for advanced renal cell carcinoma
AU - Geynisman, Daniel M.
AU - John, William S.
AU - Miller, Taavy A.
AU - Asgarisabet, Parisa
AU - Guttenplan, Sarah B.
AU - Yin, Xin
AU - Savill, Kristin M. Zimmerman
AU - Mcallister, Lindsay
AU - Rosenblatt, Lisa
N1 - © The Author(s) 2024. Published by Oxford University Press.
PY - 2024/12/19
Y1 - 2024/12/19
N2 - BACKGROUND: Given the historical underrepresentation of racial minorities in clinical trials, little is known about racial differences in outcomes of first-line therapies for advanced renal cell carcinoma (aRCC). This study described patient characteristics and clinical outcomes of first-line therapies for aRCC, including nivolumab + ipilimumab, pembrolizumab + axitinib, and tyrosine kinase inhibitors, by race in the real-world setting.METHODS: We conducted a retrospective medical chart review of patients with intermediate/poor-risk clear-cell aRCC. Treating physicians abstracted patient data from electronic medical charts.RESULTS: Among 346 patients with intermediate/poor-risk aRCC, a higher proportion of African-American/Black (n = 78) versus White (n = 268) patients had poorer baseline functional performance (ECOG-PS ≥ 2: 37.2% versus 21.3%). African-American/Black patients trended toward numerically lower overall response rates and shorter overall survival for nivolumab + ipilimumab or pembrolizumab + axitinib than White patients.CONCLUSIONS: These findings provide important insights into racial differences in first-line aRCC treatment outcomes within real-world settings. Additional research with larger sample sizes is warranted.
AB - BACKGROUND: Given the historical underrepresentation of racial minorities in clinical trials, little is known about racial differences in outcomes of first-line therapies for advanced renal cell carcinoma (aRCC). This study described patient characteristics and clinical outcomes of first-line therapies for aRCC, including nivolumab + ipilimumab, pembrolizumab + axitinib, and tyrosine kinase inhibitors, by race in the real-world setting.METHODS: We conducted a retrospective medical chart review of patients with intermediate/poor-risk clear-cell aRCC. Treating physicians abstracted patient data from electronic medical charts.RESULTS: Among 346 patients with intermediate/poor-risk aRCC, a higher proportion of African-American/Black (n = 78) versus White (n = 268) patients had poorer baseline functional performance (ECOG-PS ≥ 2: 37.2% versus 21.3%). African-American/Black patients trended toward numerically lower overall response rates and shorter overall survival for nivolumab + ipilimumab or pembrolizumab + axitinib than White patients.CONCLUSIONS: These findings provide important insights into racial differences in first-line aRCC treatment outcomes within real-world settings. Additional research with larger sample sizes is warranted.
KW - Ethnic and racial minorities
KW - Nivolumab
KW - Pembrolizumab
KW - Renal cell carcinoma
KW - Tyrosine kinase inhibitors
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=purepublist2023&SrcAuth=WosAPI&KeyUT=WOS:001380474100001&DestLinkType=FullRecord&DestApp=WOS_CPL
U2 - 10.1093/oncolo/oyae354
DO - 10.1093/oncolo/oyae354
M3 - Article
C2 - 39703163
SN - 1083-7159
JO - Oncologist
JF - Oncologist
ER -